Saturday, 14 November 2026European Markets

SPAREBANKEN ØST And SPBK 1 NORDMØRE Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - SPAREBANKEN ØST (SPOG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SPAREBANKEN ØST (SPOG.OL) kr51.80 7.55% 6.25%
SPBK 1 NORDMØRE (SNOR.OL) kr135.00 3.94% 6.44%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPAREBANKEN ØST (SPOG.OL)

7.55% Forward Dividend Yield and 6.25% Return On Equity

Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; mortgages on homes; and debenture financing for second-hand cars, as well as services in the areas of financing, savings and investment, and money-transfer. It also distributes insurance, fund shares, interest rate hedging, and currency, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr6.62.

PE Ratio

SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.82. Meaning, the purchaser of the share is investing kr7.82 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.25%.

More news about SPAREBANKEN ØST.

2. SPBK 1 NORDMØRE (SNOR.OL)

3.94% Forward Dividend Yield and 6.44% Return On Equity

SpareBank 1 Nordmøre provides various banking services in Norway. The company offers savings and deposit accounts; car, motorcycle, boat, and construction loans; and mortgages. It also provides business insurance products, which include liability, auto, mortgage, operating loss, asset, commercial, and project insurance products; personal insurance products, such as life, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. In addition, the company offers bank guarantees, trade credit products, and operating credit products for agriculture, as well as factoring, leasing, and repayment products and services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre is a subsidiary of SpareBank 1 Gruppen AS.

Earnings Per Share

As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr9.31.

PE Ratio

SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 14.5. Meaning, the purchaser of the share is investing kr14.5 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.44%.

More news about SPBK 1 NORDMØRE.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com